Every material Form 8-K Vanda Pharmaceuticals Inc. has filed with the SEC since May 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Vanda Pharmaceuticals reported third-quarter 2026 total net product sales of $69.8 million, up 24% from a year earlier and 38% from the second quarter, and updated its 2026 guidance to total revenue of greater than $240 million. The company still posted a net loss of $22.6 million, or $0.37 per diluted share, though that was roughly flat with the year-earlier loss and well below the $62.5 million second-quarter loss.
Q3 2026 total net product sales were $69.8 million, up 24% from $56.3 million in Q3 2025 and up 38% from $50.5 million in Q2 2026.
Q3 2026 net loss was $22.6 million (diluted loss per share $0.37), compared with a net loss of $22.6 million ($0.38 per share) in Q3 2025.
Total operating expenses were $93.3 million, down 18% from $114.3 million in Q2 2026.
Cash, cash equivalents and marketable securities totaled $140.5 million as of September 30, 2026, a decrease of $29.5 million in the quarter.
Vanda Pharmaceuticals reported second quarter 2026 total net product sales of $50.5 million, down 4% from $52.6 million a year earlier, as HETLIOZ sales fell 66% while Fanapt rose 23%. The net loss widened to $62.5 million, or $1.04 per diluted share, from $27.2 million, or $0.46, as operating expenses rose, and the company reiterated its full-year 2026 total revenue guidance of $240 million to $290 million.
Q2 2026 total net product sales were $50.5 million, down 4% year over year; Fanapt rose 23% to $36.0 million while HETLIOZ fell 66% to $5.6 million.
Q2 2026 net loss was $62.5 million ($1.04 per diluted share), compared with $27.2 million ($0.46) in Q2 2025.
Approximately $7.0 million of HETLIOZ orders shipped June 29, 2026 are excluded from Q2 sales and will be recognized in Q3 2026.
Cash, cash equivalents and marketable securities were $170.0 million at June 30, 2026, with funding expected through at least the end of 2027.
Vanda reported first-quarter 2026 total revenue of $51.7 million, up 3% from $50.0 million a year earlier, led by 26% growth in Fanapt net product sales. The net loss widened to $48.6 million, or $0.82 per share, from $29.5 million, or $0.50 per share, as operating expenses rose, and the company raised its full-year 2026 total revenue guidance to $240 million to $290 million from $230 million to $260 million, including $10 million to $30 million from the newly launched NEREUS.
Q1 2026 total net product sales were $51.7 million, up 3% from $50.0 million in Q1 2025; Fanapt rose 26% to $29.6 million while HETLIOZ fell 24% to $15.9 million.
Net loss was $48.6 million ($0.82 per diluted share) versus $29.5 million ($0.50 per share) in Q1 2025; selling, general and administrative expense rose to $68.4 million from $50.1 million.
Full-year 2026 total revenue guidance was raised to $240 million to $290 million from $230 million to $260 million, with NEREUS expected to contribute $10 million to $30 million.
Cash, cash equivalents and marketable securities totaled $202.3 million as of March 31, 2026, down $61.5 million in the quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Vanda Pharmaceuticals Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →